NCT04772547View on ClinicalTrials.gov

VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 22, 2021

Primary Completion Date

June 7, 2023

Study Completion Date

January 23, 2024

Conditions
Status Epilepticus, ElectrographicComa
Interventions
DRUG

Vigabatrin Only Product

enteral medication administration, serial blood draws, and outcome assessment

Trial Locations (1)

32610

University of Florida, Gainesville

All Listed Sponsors
collaborator

Yale University

OTHER

collaborator

Thomas Jefferson University

OTHER

collaborator

American Heart Association

OTHER

lead

University of Florida

OTHER

NCT04772547 - VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa | Biotech Hunter | Biotech Hunter